BriaCell to Present Clinical and Survival Data in Advanced Metastatic Breast Cancer at the 2023 AACR Annual Meeting
15 mars 2023 09h15 HE
|
BriaCell Therapeutics Corp.
PHILADELPHIA and VANCOUVER, British Columbia, March 15, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage...
BriaCell Reports Positive Survival Data in Advanced Metastatic Breast Cancer
23 févr. 2023 08h00 HE
|
BriaCell Therapeutics Corp.
9 of 11 women remain alive from 2021/2022 dosing, highlighting strong survival benefits.Remains well tolerated with no dose limiting toxicities.Primary endpoint in pending pivotal trial will be...
BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting
09 févr. 2023 23h09 HE
|
BriaCell Therapeutics Corp.
PHILADELPHIA and VANCOUVER, British Columbia, Feb. 09, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX:BCT) (“BriaCell” or the “Company”), a clinical-stage...
BriaCell CEO Letter to Shareholders
24 janv. 2023 09h07 HE
|
BriaCell Therapeutics Corp.
Positive FDA feedback on our pivotal study for lead clinical candidate Bria-IMT™ in combination with a checkpoint inhibitor could greatly accelerate the path to commercialization.Successful completion...
BriaCell to Investigate Alleged Illegal Trading of Public Securities
23 janv. 2023 08h41 HE
|
BriaCell Therapeutics Corp.
PHILADELPHIA and VANCOUVER, British Columbia, Jan. 23, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage...
BriaCell Announces Positive End of Phase II Meeting with the FDA for Bria-IMT™ Combination in Advanced Metastatic Breast Cancer
18 janv. 2023 08h47 HE
|
BriaCell Therapeutics Corp.
BriaCell has received agreement and positive feedback from its End of Phase II meeting with the FDA for lead clinical candidate, Bria-IMT™ in combination with a checkpoint inhibitor, in advanced...
BriaCell Announces New Patent Issuance, Bria-OTS™ IND Timing Guidance, and Additional Clinical Sites to Boost Enrolment
10 janv. 2023 09h00 HE
|
BriaCell Therapeutics Corp.
BriaCell’s new patent protects its novel personalized off-the-shelf cell-based technology for breast cancer and multiple other cancer indications until 2040.BriaCell expects to initiate its Bria-OTS™...
BriaCell Announces Positive Clinical and Quality of Life Data in Advanced Metastatic Breast Cancer at 2022 San Antonio Breast Cancer Symposium®
08 déc. 2022 09h25 HE
|
BriaCell Therapeutics Corp.
Positive clinical data reported includes tumor shrinkage, disease control, progression free survival, and potential long term survival benefit in advanced metastatic breast cancer patients treated...
BriaCell CEO Discusses Positive Clinical Results of its Breast Cancer Immunotherapy Treatment in an Audio Interview with SmallCapVoice.com
15 nov. 2022 08h00 HE
|
Briacell Therapeutics Corp.
AUSTIN, Texas, Nov. 15, 2022 (GLOBE NEWSWIRE) -- SmallCapVoice.com Inc. (“SCV”) announces the availability of a new audio interview with Dr. Bill Williams, CEO of BriaCell Therapeutics Corp....
BriaCell Reports Positive Breast Cancer Efficacy Data with Bria-IMT™ Immunotherapy Treatment at SITC Annual Meeting
10 nov. 2022 09h00 HE
|
BriaCell Therapeutics Corp.
Bria-IMT™ regimen in combination with Incyte’s retifanlimab produced evidence of disease control, tumor shrinkage, and potential survival benefit amongst BriaCell’s recent 12 patient cohort in...